Laos has received a new shipment of the Pfizer BioNTech Covid-19 vaccine donated by the United States through the COVAX Facility.
The Pfizer BioNTech vaccine has been reviewed for safety and efficacy by WHO and is the first COVID-19 vaccine recommended by WHO for use in individuals age 12 and above. These vaccines will protect lives in Laos and help prevent dangerous new variants from spreading.
This latest shipment consists of 799,110 doses of the Pfizer BioNTech vaccine and is the first of two shipments planned for delivery to Laos.
The combined total of both shipments is 1,698,840 doses, with the second shipment of 899,730 doses set to arrive in mid-January.
This donation builds on the one million doses of the Johnson & Johnson vaccines the United States donated to Laos in July 2021.
The shipment was received by Lao Minister of Health, Dr. Bounfeng Phoummalaysith at Wattay International Airport, and witnessed by Ms. Joy Michiko Sakurai, U.S. Charge d’affaires to Laos, Mr. Cullen Hughes, acting Country Representative for the U.S. Agency for International Development (USAID), Ms. Leotes Helin, UNICEF Representative a.i. to Laos, and Dr. Yu Lee Park, WHO Officer-in-charge to Laos.
A formal handover ceremony for the two shipments between the Government of Lao PDR and the United States will be organized in early 2022 once the second shipment has been delivered.
The Pfizer BioNTech vaccines provided by the United States will be provided to priority groups as per the National Deployment and Vaccination Plan. These include adolescents aged 12 to 17 years as well as other priority groups including people 60 years and above, people with underlying health conditions, and pregnant women.
This contribution from the United States will support Laos in its efforts toward its goal of vaccinating 80 percent of its population by the end of 2022 and will contribute to the COVAX Facility’s mission of ensuring global equitable access to Covid-19 vaccines during the pandemic.